Thursday, 19 April 2018 - 10:32
  • it
  • de
  • en
  • fr

Novo Nordisk

Novo Nordisk’s Ozempic approved also in Europe

Denmark-based Novo Nordisk yesterday announced that the European Commission has approved Ozempic (semaglutide) for the treatment of type-2 diabetes as a once-weekly treatment in a Multi-Dose Pen. Novo Nordisk expects to launch Ozempic in Europe in H2 2018. Ozempic has…

Diabetes business increasingly struggling

In the past, the diabetes business used to deliver excellent margins and considerable growth rate, which encouraged many companies to join it and launch new products. Increased competition and pressure on prices by authorities have resulted in the current global-scale…

Novo Nordisk’s growth slows down

Novo Nordisk has announced today its 2017 financial results, which are not as positive as analysts expected, thus shares have declined by over 6% (Copenhagen). Sales were DKK112bn (€15bn) and reported operating profit was DKK49bn (+1%). The Diabetes care and…

Battle over Ablynx begins

Bloomberg has reported that Denmark-based Novo Nordisk is preparing a new bid to acquire Belgium-based biotech Ablynx. The offer would significantly improve the previous one-€2.6bn-and could be submitted as early as next week. Ablynx has tried to enter into talks…

Novo Nordisk offers €2.6bn for Belgium-based Ablynx

The Belgian biotech sector appears to be fairly attractive to the big pharma. After last Friday’s announcement that Takeda had acquired Belgium-based Tigenix for €520m, Denmark-based Novo Nordisk has announced today it has offered €2.6bn for Belgian biotech company Ablynx….

Positive momentum for Novo: Ozempic (semaglutide) approved

Novo Nordisk yesterday announced that FDA has approved Ozempic (semaglutide), GLP-1’s analog, and the Danish group’s shares have soon risen over 3% (Copenhagen). Ozempic is proposed as a once-weekly injection. The new product will be sold at $676 per prescription….

NovoNordisk’s CSO openly addresses state of pharma sector

Novo Nordisk’s CSO Mads Krogsgaard has addressed in a long interview the overall state of the pharma sector. The Danish manager has voiced his skepticism about the market’s increasing interest in the NASH (Non-Alcoholic Steatohepatitis) business, that he deems unjustified,…

Novo Nordisk targets a new treatment area through an acquisition

Danish economic-financial daily Borsen today has reported a statement by Novo Nordisk’s head of research Peter Kurthals, who has said that the group is planning to access a new treatment area through a large acquisition. Novo Nordisk is already focusing…

Novo Nordisk discloses ambitious development plans for obesity drugs

Denmark-based Novo Nordisk yesterday announced at a meeting with investors that it plans to conduct a Phase-III PIONEER clinical trial with as many as 4,500 patients with obesity, assessing the investigational drug semaglutide (NN9536). The decision reflects the highly positive…

Novo’s Tresiba approved in China

Novo Nordisk announced that the China Food and Drug Administration (CFDA) has approved Tresiba (insulin degludec) for diabetes treatment. The product is a basal, new-generation insulin, to be taken once daily, that provides an ultra-long duration of action. Tresiba has…

Novo’s Victoza, new indication to reduce CV risk

Novo Nordisk announced that the FDA approved a new indication for Victoza (liraglutide) to reduce the risk of major cardiovascular events in adults with type 2 diabetes and cardiovascular disease. The indication is based on the results from the LEADER…

The best drug is not always a guarantee for the best financial results

Novo Nordisk demonstrated to investors and analysts that the best and most advanced drug is not always the product which ensures the best financial results. The Denmark-based pharmaceutical giant recently launched on the market Tresiba, a novel, advanced insulin for…

Novo focuses on new obesity therapy Semaglutide

Novo Nordisk reiterated last week, during a presentation to investors and analysts, the importance of its new investigational obesity therapy semaglutide for its future. Novo recently completed a Phase II clinical trial with semaglutide vs Saxenda vs Placebo, enrolling 1,000…

Novo’s Victoza, positive opinion by FDA EMDAC on cardiovascular outcomes

Novo Nordisk announced that FDA EMDAC (Endocrinologic and Metabolic Drugs Advisory Committee) discussed the sNDA (supplemental New Drug Application) submitted by the company in order to have data on cardiovascular outcomes from the LEADER trial included in Victoza’s label (liraglutide)….

Novo Nordisk, Innate Pharma sign agreement for novel cancer immunotherapy

Innate Pharma today announced it entered into an agreement with Novo Nordisk, granting the France-based company worldwide exclusive rights to develop and commercialize the first drug (IPH5401) in a new class of immuno-oncology therapies. It is a new investigational anti-C5aR…

FDA approves Novo Nordisk’s Rebinyn for hemophilia B

Novo Nordisk announced that FDA granted authorization to Rebinyn (nonacog beta pegol) for the treatment of infants and adults with hemophilia B. The product is indicated for on-demand treatment and control of bleeding episodes and the perioperative management of bleeding…

Novo Nordisk growing again: excellent first quarter

The largest producer of insulins worldwide, Denmark’s Novo Nordisk, yesterday announced its Q1 2017 results to the financial community. Sales of the group, led by new CEO Lars Fruergaard Jørgensen, were up 5% (DKr28.45bn), EBITDA was up 10% and net…

Novo Nordisk to target Global Blood Therapeutics ($1.4bn)

Novo Nordisk is reportedly in talks to acquire US-based Global Blood Therapeutics Inc, a biotech company focused on developing therapies targeting blood diseases. Global Blood Therapeutics shares rose more than 32% (NASDAQ) on the news, taking the group’s market capitalization…

Novo Nordisk uncertain about the future of the diabetes market

Novo Nordisk, the global leader in diabetes care, reported its fourth quarter and full year 2016 results, which did not meet predictions by analysts. The Danish group’s sales totaled $1.26bn in Q4 and $0.5 in EPS, whereas analysts expected $0.52….

The European Commission approves Novo Nordisk’s Fiasp

Novo Nordisk announced that the European Commission has granted marketing authorization for Fiasp (fast-acting insulin aspart) for the treatment of adult patients with diabetes. The product is a fast-acting insulin which ensures improved mealtime and overall glucose control with a…

Sanofi sues Novo Nordisk in the US

Sanofi has sued Novo Nordisk in the US, accusing it of false claims regarding the availability of Sanofi’s insulin drugs, Reuters reported. The Dutch company allegedly said that Sanofi’s products would no longer be available for many US patients. The…

FDA approves pediatric use of Novo’s Tresiba

Novo Nordisk announced that FDA has extended the use of Tresiba (degludec) to children one year of age and older. The product is a basal, long-acting insulin to be administered once-daily to patients with type 1 and type 2 diabetes,…

Express Scripts to collaborate with Lilly to control insulins costs

Eli Lilly and Express Scripts are collaborating in order to offer interesting discounts on some diabetes treatments. The discounted prices will apply as of 1 January 2017 and will cover especially Humalog and Humulin, but also the Lantus follow-on biologic…